Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Oct 2025
October is Breast Cancer Awareness Month, a time to spotlight a disease that will affect hundreds of thousands of Americans this year. In the U.S., a new case of breast cancer is diagnosed about every two minutes, with more ...
Read Full NewsThe FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.
A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.
Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
1.
Remote monitoring can improve recovery from cancer surgery
2.
For relapsed or resistant DLBCL, odronextamab produced positive results.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.
5.
GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer
1.
Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances
2.
Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options
3.
Understanding the HAS-BLED Score: What It Is and Why It Matters
4.
Case-Based Learning: Unexplained Hemolysis With Normal Peripheral Smear
5.
Personalized Oncolytic Virus Combinations: Current Evidence and Clinical Implications
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Navigating the Complexities of Ph Negative ALL - Part XVI
2.
Navigating the Complexities of Ph Negative ALL - Part IV
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
4.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
5.
Teaching Coagulation Pathways Through Interactive Thrombin Generation Models
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge